当前位置: X-MOL 学术J. Steroid Biochem. Mol. Biol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
The Vitamin D Assessment (ViDA) study - Design and main findings.
The Journal of Steroid Biochemistry and Molecular Biology ( IF 4.1 ) Pub Date : 2019-12-03 , DOI: 10.1016/j.jsbmb.2019.105562
Robert Scragg 1
Affiliation  

Accumulating evidence from observational studies indicates that vitamin D status is inversely associated with a many non-skeletal diseases. This has initiated the conduct of several large clinical trials to determine if high dose vitamin D supplementation (≥ 2000 IU/day or monthly equivalent) prevents non-skeletal disease including cardiovascular disease, cancer and mortality. One of these trials is the Vitamin D Assessment (ViDA) Study which recruited 5110 participants, aged 50-84 years, mostly from primary care practices in Auckland, New Zealand. The intervention was a capsule that contained either 100,000 IU vitamin D3 or placebo, two of which were taken by each participant soon after randomization, and then monthly up to 31 July 2015 (median follow-up 3.3 years). Information on study outcomes came from self-completed questionnaires and health data collected routinely by the Ministry of Health. There was no effect of vitamin D on the main outcomes: cardiovascular disease, acute respiratory infections, non-vertebral fractures, falls and all cancer. In contrast, vitamin D increased persistence with taking statins among participants on long term statin therapy. Beneficial effects were seen also for lung function among ever smokers (especially if vitamin D deficient), and in participants with low 25-hydroxyvitamin D levels for bone mineral density and arterial function. The findings support future research being carried out mainly in people who are vitamin D deficient, although there are practical and ethical issues in recruiting such people into future vitamin D supplementation trials.

中文翻译:

维生素D评估(ViDA)研究-设计和主要发现。

观察性研究的越来越多的证据表明,维生素D的状态与许多非骨骼疾病呈负相关。这已经启动了几项大型临床试验,以确定高剂量的维生素D补充剂(≥2000 IU /天或每月当量)是否可以预防包括心血管疾病,癌症和死亡率在内的非骨骼疾病。这些试验之一是维生素D评估(ViDA)研究,该研究招募了5110名年龄在50-84岁之间的参与者,主要来自新西兰奥克兰的初级保健实践。干预措施是一个装有100,000 IU维生素D3或安慰剂的胶囊,每位参与者在随机分组后立即服用其中的两种,然后每月一次直至2015年7月31日(中位随访时间为3.3年)。有关研究结果的信息来自卫生部常规收集的自我填写的调查表和健康数据。维生素D对主要结局没有影响:心血管疾病,急性呼吸道感染,非椎骨骨折,跌倒和所有癌症。相反,长期接受他汀类药物治疗的参与者服用他汀类药物后,维生素D会增加持久性。在吸烟者中(尤其是维生素D缺乏的情况下),以及骨矿物质密度和动脉功能的25-羟基维生素D水平低的参与者中,肺功能也被认为是有益的。这些发现支持了主要针对维生素D缺乏者的未来研究,尽管在招募此类人参加未来的维生素D补充试验方面存在实用和道德问题。
更新日期:2019-12-03
down
wechat
bug